.....Hamilton Lane Advisors LLC.......purchased 12,976 shares during the first quarter.
I imagine they cannot be happy with some of the shenanigans going on here affecting their investment.
.....California Public Employees Retirement System purchased 22,057 shares of Insmed in the 1st Quarter. They now have a total of 122,857 shares.
I wonder if Sacramento is looking for Terry and his cohorts for their work in devaluing their investment by their shenanigans? They might find him by the water....Surf's up!!
Are you suggesting a starting bid price of 4 times Piper Jaffray's 12 month target price of 51? What about Pfizer?
Makes sense to me, Rook. In fact, I think you have the stars aligning with my "old" favorite number. By that, I mean, if you take the numbers with a "B" after it, add them from left to right, you get.....see what I mean?
......as of 4/15/14........UP approximately 3,500 shares.
Avg Daily Share Volume
Days To Cover
4/15/2014 3,417,075 981,074 3.482994
3/31/2014 3,413,412 1,531,019 2.229503
Here's something I found from before.....just in case there are some here that believe us (LOL)
"During the 30-week period of Iplex usage that comprised the first half (26 weeks and follow-up four-week period) of the one year authorized investigational new drug trial, there was a remarkable parity between the apparent responsiveness of the individual patients compared to the aggregated group of patients at large. Symptoms monitored for their absence, presence, or their degree of severity included the following: Hyperreflexia; Tongue Movement; Swallow; Hand Strength; Shoulder Strength; Fatigue; Clonus; Nausea; Atrophy; Breathing; Lability; Lower Arm Strength; Fasciculations; Dizziness; Cramps/Pain; Weakness; Balance; Speech; Upper Arm Strength; Tremor/Palsy; Rigidity; Libido. In the consolidated 30 week period, individual symptoms showed a maximum decline of 9% (Balance) followed by 6%(Tremor/Palsy). The maximum improvement of an individual symptom was 39% (Fasciculations) followed by 28% (Fatigue). The critical function (Swallowing) improved by 25% and Breathing improved by 1%. Compared to the normal relentless worsening in virtually all symptoms over any continuous 30-week period of time, the use of Iplex appears to have stabilized, if not improved, the condition of its users. Those using Iplex demonstrated an average improvement of symptoms of 9.3% (all symptoms combined) after the 30-week period. There were no adverse events or serious adverse events during this 30-week period."
Do you have a link to see this percentage? I know you can't put an actual link but go ahead and type it in and put a lot of spaces in (LOL)
......appears to be something to look forward to in the merry, merry month of May. Based upon some things that should happen:
1) 1st Quarter Report
2) As reported by someone else--Mid May FDA response to Insmed's request regarding Breakthrough Therapy
3) May 20th -- poster presentation/discussion at the American Thoracic Therapy International International Conference in San Diego.
Any additions or subtractions?
That brings the total of Open postings to 15. One is temporary and one is a summer intern. This doesn't sound like a company who is expecting anything less than a good outcome.